Search research articles
Contact Us
Filters
Showing results (301-310 of 343) with videos related to
Page
of 35
Sort By:
Rheumatology (Oxford, England)
|
March 22, 2021
What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study
Laura C Coates, Danielle E Robinson, Ana-Maria Orbai, et al.
The Journal of Investigative Dermatology
|
December 21, 2020
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis-Correction
Catherine H Smith, Satveer K Mahil, Zenas Z N Yiu, et al.
Lancet (London, England)
|
October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip Mease, Laura C Coates, Philip S Helliwell, et al.
RMD Open
|
February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Laura C Coates, Robert Landewé, Iain B McInnes, et al.
Annals of the Rheumatic Diseases
|
June 5, 2026
Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis
Tommy K Annfeldt, Mina N Händel, Tobias Haugegaard, et al.
Seminars in Arthritis and Rheumatism
|
January 6, 2026
Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study
Ying-Ying Leung, Tobias Haugegaard, Tommy Kok Annfeldt, et al.
Scientific Data
|
February 22, 2024
Ethnicity data resource in population-wide health records: completeness, coverage and granularity of diversity
Marta Pineda-Moncusí, Freya Allery, Antonella Delmestri, et al.
The Lancet. Respiratory Medicine
|
June 30, 2022
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Abhishek Abhishek, Rosemary J Boyton, Nicholas Peckham, et al.
Lancet (London, England)
|
December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
The Journal of Rheumatology. Supplement
|
June 3, 2018
Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
Richard Holland, William Tillett, Alexis Ogdie, et al.
Page
of 35
Search research articles
Search
Showing results (301-310 of 343) with videos related to
Sort By:
Page
of 35
Rheumatology (Oxford, England)
|
March 22, 2021
What influences patients' opinion of remission and low disease activity in psoriatic arthritis? Principal component analysis of an international study
Laura C Coates, Danielle E Robinson, Ana-Maria Orbai, et al.
The Journal of Investigative Dermatology
|
December 21, 2020
Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis-Correction
Catherine H Smith, Satveer K Mahil, Zenas Z N Yiu, et al.
Lancet (London, England)
|
October 27, 2018
Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial
Philip Mease, Laura C Coates, Philip S Helliwell, et al.
RMD Open
|
February 22, 2024
Bimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Laura C Coates, Robert Landewé, Iain B McInnes, et al.
Annals of the Rheumatic Diseases
|
June 5, 2026
Composite outcome measures that successfully differentiate active treatments from placebo in psoriatic arthritis trials: a GRAPPA-OMERACT systematic review and network meta-analysis
Tommy K Annfeldt, Mina N Händel, Tobias Haugegaard, et al.
Seminars in Arthritis and Rheumatism
|
January 6, 2026
Determining the best discriminatory physical functioning outcome measurement instrument for psoriatic arthritis trials: A meta-epidemiological study
Ying-Ying Leung, Tobias Haugegaard, Tommy Kok Annfeldt, et al.
Scientific Data
|
February 22, 2024
Ethnicity data resource in population-wide health records: completeness, coverage and granularity of diversity
Marta Pineda-Moncusí, Freya Allery, Antonella Delmestri, et al.
The Lancet. Respiratory Medicine
|
June 30, 2022
Effect of a 2-week interruption in methotrexate treatment versus continued treatment on COVID-19 booster vaccine immunity in adults with inflammatory conditions (VROOM study): a randomised, open label, superiority trial
Abhishek Abhishek, Rosemary J Boyton, Nicholas Peckham, et al.
Lancet (London, England)
|
December 10, 2022
Bimekizumab in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor-α inhibitors: a randomised, double-blind, placebo-controlled, phase 3 trial (BE COMPLETE)
Joseph F Merola, Robert Landewé, Iain B McInnes, et al.
The Journal of Rheumatology. Supplement
|
June 3, 2018
Content and Face Validity and Feasibility of 5 Candidate Instruments for Psoriatic Arthritis Randomized Controlled Trials: The PsA OMERACT Core Set Workshop at the GRAPPA 2017 Annual Meeting
Richard Holland, William Tillett, Alexis Ogdie, et al.
Page
of 35